Tag Archives: against

Eli Lilly’s Reyvow, squaring off against AbbVie and Biohaven, posts data showing early and lasting migraine relief

With several new acute migraine treatments vying for market share, Eli Lilly is touting new data on Reyvow showing the med can provide patients “pain freedom” in as little as one hour, plus sustained relief for up to two days. In a phase 3 trial called Centurion, patients who took Lilly’s new drug at the 200mg dose were 4.6 times more likely to experience pain… Read More »

Cancer mortality continues steady decline, driven by progress against lung cancer

The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported. The news comes from Cancer Statistics, 2020, the latest edition of the American Cancer Society’s annual report on cancer rates and trends. The steady 26-year decline in… Read More »